02552.HK
Hua Medicine (Shanghai) Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 2.31
−1.28%Year over year
Reported trailing growth
- Revenue
- +73.9%
- EBITDA
- +64.3%
- EBIT
- +54.8%
- EPS
- —
- Free cash flow
- +78.3%
- Operating cash flow
- +81.1%
Forward estimates
Based on analyst estimates
- Revenue
- +265.4%
- EBITDA
- +1860.1%
- EPS
- +1024.6%
Three-year CAGR
- Revenue
- +201.0%
- EBITDA
- +68.3%
- EBIT
- +60.0%
- Net income
- +530.8%
- EPS
- +536.0%
- Free cash flow
- +85.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026